C17orf112 Activators
The functional modulation of C17orf112 involves a diverse array of chemical compounds, each targeting specific signaling pathways and mechanisms within the cell. Isoproterenol and BIM-26226, through their effects on the beta-adrenergic receptor, modulate intracellular cAMP levels and PKA activity, potentially influencing pathways where C17orf112 is involved. This modulation can lead to enhanced phosphorylation of proteins in these pathways, thereby influencing C17orf112's activity. Calcium ionophores like Ionomycin increase intracellular calcium concentrations, activating calcium-dependent pathways that may intersect with those involving C17orf112, thus potentially enhancing its function.
Furthermore, inhibitors like PD98059 and SB431542, targeting the MEK and TGF-beta receptors respectively, alter key signaling cascades. PD98059's inhibition of the MAPK/ERK pathway could lead to the activation of alternative signaling routes involving C17orf112, while SB431542 might modulate TGF-beta signaling pathways associated with C17orf112. Rapamycin, an mTOR inhibitor, and 2-Deoxy-D-glucose, a glycolysis inhibitor, impact cellular metabolism and growth pathways, potentially affecting those where C17orf112 is active. Additionally, Okadaic Acid's inhibition of protein phosphatases PP1 and PP2A can alter the phosphorylation state of proteins within C17orf112's pathways, potentially enhancing its activity. Y-27632 and ZM447439, as inhibitors of ROCK and Aurora kinase respectively, influence cytoskeletal dynamics and cell cycle-related pathways, which could impact C17orf112's activity. Temozolomide, through its DNA-damaging effects, and Niclosamide, via inhibiting the STAT3 signaling pathway, also potentially affect pathways involving C17orf112. These chemical compounds, through their targeted effects on specific cellular signaling mechanisms, collectively facilitate the modulation of C17orf112's activity, illustrating the intricate web of cellular regulation and the nuanced roles these activators play in influencing the function of this specific protein.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, elevates cAMP levels similarly to Forskolin. This increase in cAMP can lead to the activation of PKA, which may enhance C17orf112 activity by phosphorylating associated proteins in relevant pathways. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore like A23187. It increases intracellular calcium concentration, potentially activating pathways that intersect with those involving C17orf112, hence enhancing its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is an MEK inhibitor, similar in function to U0126. By inhibiting MEK, it can impact the MAPK/ERK pathway, potentially leading to the activation of signaling routes where C17orf112 is involved. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is a key regulator of cell growth and proliferation. This inhibition can alter signaling pathways, potentially affecting those where C17orf112 is active. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
2-Deoxy-D-glucose acts as a glycolysis inhibitor. By interfering with glycolytic pathways, it can influence cellular metabolism, potentially impacting signaling pathways associated with C17orf112. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542 is an inhibitor of the TGF-beta receptor. By inhibiting this receptor, it can modulate the TGF-beta signaling pathway, potentially affecting pathways where C17orf112 is involved. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases PP1 and PP2A. Inhibition of these phosphatases can lead to altered phosphorylation states of proteins in pathways involving C17orf112, potentially enhancing its activity. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor. By inhibiting ROCK, it can influence cytoskeletal dynamics and related signaling pathways, potentially impacting C17orf112 activity. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM447439 is an Aurora kinase inhibitor. It can modulate cell cycle-related pathways, potentially affecting those where C17orf112 is involved. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $89.00 $250.00 | 32 | |
Temozolomide, a DNA alkylating agent, can cause DNA damage and impact cell cycle pathways. This influence can potentially affect signaling pathways involving C17orf112. | ||||||